Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway
Hypoxia-mediated chemoresistance has been regarded as an important obstacle in the development of cancer treatment. Knockdown of krüppel-like factor 5 (KLF5) was reported to inhibit hypoxia-induced cell survival and promote cell apoptosis in non-small cell lung cancer (NSCLC) cells via direct regulation of hypoxia inducible factor-1α (HIF-1α) expression. However, the roles of KLF5 in the development of hypoxia-induced cisplatin (DDP) resistance and its underlying mechanism in NSCLC cells remain to be further elucidated.
Western blot was performed to determine the protein levels of KLF5, P-glycoprotein (P-gp) and HIF-1α in treated NSCLC cells. Cell survival was examined by MTT assay. The effect of KLF5 knockdown on hypoxia-induced glycolysis was assessed by measuring glucose consumption and lactate production. The effect of KLF5 knockdown on the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway was analyzed by western blot.
Hypoxia upregulated the expression of KLF5 in NSCLC cells. KLF5 knockdown suppressed hypoxia-induced DDP resistance in NSCLC cells, as demonstrated by the increased cytotoxic effects of DDP and reduced P-gp expression in NSCLC cells in hypoxia. Moreover, KLF5 knockdown inhibited hypoxia-induced HIF-1α expression and glycolysis, and KLF5 knockdown suppressed hypoxia-induced DDP resistance by inhibiting HIF-1α-dependent glycolysis in NSCLC cells. Furthermore, KLF5 knockdown suppressed hypoxia-induced activation of the PI3K/Akt/mTOR pathway in NSCLC cells and KLF5 overexpression promoted hypoxia-induced DDP resistance in NSCLC cells through activation of the PI3K/Akt/mTOR pathway.
KLF5 knockdown could suppress hypoxia-induced DDP resistance, and its mechanism may be due to the inhibition of HIF-1α-dependent glycolysis via inactivation of the PI3K/Akt/mTOR pathway.
KeywordsKLF5 Hypoxia DDP resistance Glycolysis The PI3K/Akt/mTOR pathway NSCLC
krüppel-like factor 5
hypoxia inducible factor-1α
non-small cell lung cancer cells
protein kinase B
mammalian target of rapamycin
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
pyruvate dehydrogenase kinase-1
Lung cancer, one of the most common cancer types in women and men, is currently the predominant cause of cancer-related deaths worldwide, resulting in more than one million deaths worldwide annually . Non-small cell lung cancer (NSCLC) comprises almost 85% of all lung cancer cases . Despite the considerable improvements in early diagnosis and therapeutic approaches of NSCLC patients, the prognosis is still unsatisfactory, with the total 5-year survival rate less than 15% . Platinum-based chemotherapy is an important adjuvant therapeutic strategy for NSCLC patients . As the most widely used platinum compound, cisplatin (DDP) is the first-line chemotherapeutic agent for the treatment of NSCLC and can induce cancer cell cycle arrest and apoptotic death . However, its efficacy is often impaired due to the development of chemoresistance, which accounts for the major chemotherapy failure in both resectable and advanced NSCLC . Therefore, elucidating the molecular mechanism involved in DDP resistance of NSCLC and identifying novel molecular-targeted therapeutic approaches to overcome DDP resistance are desperately needed.
The mechanism of chemoresistance is highly complicated, in which a hypoxic microenvironment potentially plays a critical role . Hypoxia is a common phenomenon in most human solid tumors and has the potential to affect various physiological and pathological processes, such as proliferation, apoptosis, angiogenesis, and therapy resistance . Increasing clinical and experimental studies have documented that hypoxia contributes to resistance to anticancer drugs in diverse cancer cells by promoting malignant phenotypes [9, 10]. Accordingly, hypoxia-mediated chemoresistance has been regarded as an important obstacle in the development of cancer treatment . Hypoxia inducible factor-1α (HIF-1α) is an important regulator of transcription in response to hypoxia, which activates the expression of more than 60 target genes involved in cell proliferation, apoptosis, and glycolysis . It is believed that HIF-1α-induced glycolysis plays a critical role in promoting chemoresistance of NSCLC cells . Recent studies have also reported the involvement of glycolysis with chemoresistance . Therefore, inhibiting HIF-1α-induced glycolysis may be a potential approach for the reversal of hypoxia-induced chemoresistance.
Krüppel-like factor 5 (KLF5, also known as BTEB2), a member of the KLF family, is characterized by containing a highly conserved C-terminal and three independent c2h2 zinc fingers . KLF5 binds to the GC-rich DNA sequence in the promoters of target genes using its three zinc finger domains . As a DNA-binding transcriptional factor, KLF5 has been shown to have essential roles in multiple cellular processes, including tumor progression, cell proliferation, differentiation and apoptosis, in different human cancers . More importantly, KLF5 is well acknowledged to be regulated by hypoxia in tumors and acts as an upstream regulator of HIF-1α . A previous study reported that KLF5 knockdown inhibited hypoxia-induced cell survival and promoted cell apoptosis in NSCLC cells via direct regulation of HIF-1α expression . However, the roles of KLF5 in the development of hypoxia-induced DDP resistance and its underlying mechanism in NSCLC cells remain to be further elucidated.
In the present study, we demonstrated that KLF5 contributed to hypoxia-induced DDP resistance in NSCLC cells and the mechanism of KLF5 was elucidated.
Cell lines and hypoxic incubation
NSCLC cell lines H1299 and A549 were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). These cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA), 100 U/mL penicillin (Thermo Scientific, Rockford, IL, USA) and 100 μg/mL streptomycin (Thermo Scientific) in a humidified incubator at 37 °C with 21% O2 and 5% CO2 for normoxic condition. Cells were maintained in a humidified atmosphere at 37 °C under 94% N2, 1% O2 and 5% CO2 in the automated Xvivo system G300CL (BioSpherix, Lacona, NY, USA) for hypoxic condition.
siRNAs specifically against KLF5 (si-KLF5#1 and si-KLF5#2), siRNA scrambled control (si-NC), pcDNA-KLF5, pcDNA-HIF-1α, and pcDNA empty vector (Vector) were purchased from GenePharma (Shanghai, China). Cells were plated in 6-well plates at a density of 2.5 × 105 cells/well and grown to 80% confluence. Subsequently, cell transfection with these oligonucleotides or plasmids was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). At 48 h post-transfection, cells were harvested for further analysis.
Western blot analysis
Total protein was extracted from cultured cells in RIPA lysis buffer (Beyotime, Beijing, China). Protein concentration of the cell extracts was measured by BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Approximately 50 μg protein samples in each lane were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by being transferred onto PVDF membrane (EMD Millipore, Billerica, MA, USA). Following blocking with 5% nonfat dry milk in TBST buffer (20 mM Tris–HCl, pH 7.4, 150 mM NaCl and 0.1% Tween 20) for 1 h, the membranes were incubated at 4 °C overnight with the primary antibodies against KLF5, P-glycoprotein (P-gp), HIF-1α, mammalian target of rapamycin (mTOR), phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), phosphorylated-Akt (p-Akt) and β-actin (all from Abcam, Cambridge, MA, USA) and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody immunoglobulin G (IgG) (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) at room temperature for 1 h. The blots were developed by enhanced chemiluminescence reagent (GE Healthcare, Piscataway, NJ, USA).
Cell survival assay
A549 and H1299 cells were seeded into 96-well culture plates at a density of 5 × 103 cells/well and transfected with or without si-KLF5 or si-NC, pcDNA-KLF5 or Vector. At 48 h post-transfection, various concentrations of DDP (0, 5, 10, 15, 20, 25, 30, 35, and 40 μM) were added to each well and the cells were incubated in a humidified incubator under a normoxic or hypoxic condition for another 24 h. Subsequently, 20 μL of 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, St. Louis, MO, USA) was added to each well and incubated for another 4 h. Then the supernatant was discarded and 150 μL of dimethyl sulfoxide (DMSO, Sigma) was added to dissolve the dark blue crystal. Absorbance of each well was measured at 490 nm using a microplate reader (Bio-Rad, Hercules, CA, USA).
Measurement of glucose uptake and lactate
A549 and H1299 cells were seeded into 6-well plates and transfected with or without si-KLF5 si-NC, pcDNA-KLF5 or Vector, followed by incubation under a normoxic or hypoxic condition. The culture supernatant of cells was collected after transfection for 48 h and the amount of glucose and lactate in the supernatant was measured using a glucose uptake colorimetric assay kit (Sigma) and a Lactic Acid assay kit (KeyGen, Nanjing, China), respectively.
All results were expressed as the mean ± standard deviation (SD). Statistical analysis was performed using SPSS statistical software (version 18.0, SPSS, Inc., Chicago, IL, USA). The statistical differences between groups were determined by the two-tailed unpaired Student’s t test. P < 0.05 was considered to indicate a statistically significance.
Hypoxia upregulated the expression of KLF5 in NSCLC cells
KLF5 knockdown suppressed hypoxia-induced DDP resistance in NSCLC cells
KLF5 knockdown inhibited hypoxia-induced HIF-1α expression and glycolysis in NSCLC cells
KLF5 knockdown suppressed hypoxia-induced DDP resistance by inhibiting HIF-1α-dependent glycolysis in NSCLC cells
KLF5 knockdown inhibited hypoxia-induced activation of the PI3K/Akt/mTOR pathway in NSCLC cells
KLF5 overexpression promoted hypoxia-induced DDP resistance in NSCLC cells through activation of the PI3K/Akt/mTOR pathway
It has been well documented that hypoxia-induced DDP resistance is one of the major obstacles in the chemotherapy of various solid tumors including NSCLC . Therefore, it is urgently needed to figure out novel and effective sensitizers to overcome hypoxia-induced DDP resistance. In the present study, we described that KLF5 knockdown suppressed hypoxia-induced resistance to DDP in NSCLC cells and elucidated the underlying mechanism.
Accumulating evidence suggests that KLF5 has become the focus of the research due to its crucial regulatory functions associated with diverse functions such as cell growth, proliferation, development and oncogenic processes . However, accumulating evidence has suggested a conflicting role for KLF5 in tumorigenesis. On one hand, KLF5 has been demonstrated to be upregulated in some types of human cancers, such as breast and bladder cancer, in which it contributes to tumor progression [29, 30]. On the other hand, KLF5 has been reported to be frequently deleted or downregulated in other kinds of tumors like prostate cancer and acute myeloid leukemia, in which it suppresses cancer cell growth [31, 32]. Thus, KLF5’s function as an oncogene or a tumor suppressor may depend on the types and stages of tumors [33, 34]. More recently, KLF5 was also found to be associated with drug resistance in several tumors. For instance, KLF5 has been reported to strengthen drug resistance in ovarian cancer cells by inducing survivin gene expression . Moreover, KLF5 was a dexamethasone (Dex)-induced gene that contributed to Dex-mediated drug chemoresistance in triple-negative breast cancer . More importantly, a previous study revealed that KLF5 transcriptionally repressed the expression of ATP-binding cassette subfamily G member 2 (ABCG2) and KLF5 knockdown increased the resistance of lung cancer cells to doxorubicin treatment . However, whether KLF5 was involved in hypoxia-induced DDP resistance in NSCLC remains to be explored.
In the present study, we found that KLF5 expression was significantly upregulated in NSCLC cells under a hypoxic condition, consistently with the previous study . Our study further implicated that KLF5 knockdown overturned the cytotoxic effects of DDP and suppressed the expressions of P-gp and HIF-1α in NSCLC cells under hypoxia. Moreover, HIF-1α overexpression abolished KLF5 knockdown-induced suppression of HIF-1α and P-gp expressions in NSCLC cells under hypoxia. KLF5 is well known to act as an upstream regulator of HIF-1α . Additionally, it has been shown that cancer cells develop resistance to chemotherapeutic drugs via hypoxia-induced expressions of drug-pumping proteins, such as P-gp, a well-known transcriptional target of HIF-1 . Accordingly, we concluded that KLF5 knockdown hindered hypoxia-induced DDP resistance via inhibiting P-gp expression in a HIF-1α-dependent manner.
Increased glycolysis is a major causative factor accounting for hypoxia-induced drug resistance in tumors . It has been well accepted that glycolysis is the main energy source for hypoxic cancer cells to produce large amounts of ATP, which enables malignant tumor cells to survive under a hypoxic condition . Therefore, ATP deficiency induced by glycolytic inhibition can enable cancer cells more susceptible to chemotherapeutic drugs . For example, treatment of dichloroacetate (DCA), an inhibitor of the glycolytic pathway, or genetic inhibition of pyruvate dehydrogenase kinase-1 (PDK-1), which is responsible for enhancing glycolysis, attenuated hypoxia-induced resistance to 5-fluorouracil (5-FU) in gastric cancer cells through the alteration of glucose metabolism . Baicalein reversed hypoxia-induced 5-FU resistance in gastric cancer cells through suppression of glycolysis via regulation of the PTEN/Akt/HIF-1α signaling pathway . In the present study, we demonstrated that KLF5 knockdown inhibited hypoxia-induced glycolysis in NSCLC cells, as evidenced by the reduced glucose consumption and lactate production, which was overturned by HIF-1α overexpression. Collectively, these results suggested that KLF5 knockdown inhibited hypoxia-induced DDP resistance by inhibiting HIF-1α-dependent glycolysis.
The PI3K/Akt/mTOR signaling pathway widely distributed in cells has been recognized as an important signaling pathway involved in the regulation of many cellular functions, such as cell proliferation, differentiation, survival, and apoptosis . Abnormal activation of the PI3K/Akt/mTOR pathway is frequently observed in various types of human cancers and therefore targeting this pathway might represent a key therapeutic opportunity for the treatment of tumor . Recent studies show that the PI3K/Akt/mTOR pathway plays an important role in the development of chemotherapy resistance and inhibition of the PI3K/Akt/mTOR pathway reverses drug resistance in several tumors [44, 45]. Emerging evidence suggests that activation of the PI3K/Akt signaling by hypoxia contributes to hypoxia-induced drug resistance in various human cancers [46, 47]. For example, HIF-1α-induced MAX dimerization protein 1 upregulation contributed to hypoxia-induced DDP resistance in osteosarcoma cells through activation of the PI3K/Akt pathway . Wogonin reversed hypoxia-induced multidrug resistance of human colon cancer cells via suppression of HIF-1α and glycolysis, by inhibiting the PI3K/Akt signaling pathway . Similarly, our study proved that KLF5 knockdown inhibited hypoxia-induced activation of the PI3K/Akt/mTOR pathway in NSCLC cells. Besides, KLF5 overexpression promoted hypoxia-induced DDP resistance in NSCLC cells through activation of the PI3K/Akt/mTOR pathway. Based on the above results, we concluded that KLF5 knockdown suppressed hypoxia-induced DDP resistance by inhibiting HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
In conclusion, it was demonstrated that KLF5 knockdown showed strong reversal potency of hypoxia-induced DDP resistance in NSCLC cells by inhibiting HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. Therefore, KLF5 may be a novel and promising therapeutic sensitizer to reverse hypoxia-induced DDP resistance in NSCLC cells.
TG and LC assisted in the design of study, performed experiments, analyzed/interpreted data, and drafted the manuscript; HW, HW and NH made substantial contributions to study conception and design, data analysis and interpretation, and drafting and revising the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the article.
Consent for publication
Ethics approval and consent to participate
Our study was performed with the approval of Ethics Committee of the First Affiliated Hospital of Zhengzhou University and written informed consent was obtained from every patients.
Our work is supported by the Key Project of Hanan Educational committee (17A180019) and the Fundamental Research Funds for the Henan Provincial Colleges and Universities in Henan University of Technology.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 25.Mottet D, Dumont V, Deccache Y, Demazy C, Ninane N, Raes M, et al. Regulation of hypoxia-inducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta pathway in HepG2 cells. J Biol Chem. 2003;278(33):31277–85.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.